Developing disease modifying Alkaline Phosphatase therapeutics.

AM-Pharma is a biopharmaceutical company developing a novel recombinant human alkaline phosphatase for treatments of severe inflammatory mediated diseases. Alkaline Phosphatase plays a key role as an anti inflammatory agent in various disease pathways. The Company’s lead program is focused on Acute Kidney Injury. In 2015 AM-Pharma closed a staged acquisition by Pfizer of a total deal value of $ 600 million.

  • CEO Erik van den Berg, MSc, MBA
  • Industry Biotech